Vitae Pharmaceuticals Inc (VTAE) : Awm Investment Company reduced its stake in Vitae Pharmaceuticals Inc by 2.16% during the most recent quarter end. The investment management company now holds a total of 1,177,864 shares of Vitae Pharmaceuticals Inc which is valued at $10,706,784 after selling 25,957 shares in Vitae Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Vitae Pharmaceuticals Inc makes up approximately 2.09% of Awm Investment Company’s portfolio.
Other Hedge Funds, Including , Acrospire Investment Management added VTAE to its portfolio by purchasing 614 company shares during the most recent quarter which is valued at $5,581.Oxford Asset Management boosted its stake in VTAE in the latest quarter, The investment management firm added 216,544 additional shares and now holds a total of 314,326 shares of Vitae Pharmaceuticals Inc which is valued at $2,703,204. Vitae Pharmaceuticals Inc makes up approx 0.11% of Oxford Asset Management’s portfolio.Mufg Americas Holdings Corp boosted its stake in VTAE in the latest quarter, The investment management firm added 336 additional shares and now holds a total of 566 shares of Vitae Pharmaceuticals Inc which is valued at $4,868. Quantitative Systematic Strategies sold out all of its stake in VTAE during the most recent quarter. The investment firm sold 24,301 shares of VTAE which is valued $258,806.Handelsbanken Fonder Ab boosted its stake in VTAE in the latest quarter, The investment management firm added 20,000 additional shares and now holds a total of 153,000 shares of Vitae Pharmaceuticals Inc which is valued at $1,582,020. Vitae Pharmaceuticals Inc makes up approx 0.06% of Handelsbanken Fonder Ab’s portfolio.
Vitae Pharmaceuticals Inc closed down -0.4 points or -4.66% at $8.18 with 1,66,468 shares getting traded on Wednesday. Post opening the session at $8.57, the shares hit an intraday low of $8.08 and an intraday high of $8.61 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Vitae Pharmaceuticals Inc reported $-0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.41.Analysts expectations of $ .01.The company’s revenue was down -98.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.45 EPS.
Many Wall Street Analysts have commented on Vitae Pharmaceuticals Inc. Vitae Pharmaceuticals Inc was Downgraded by JMP Securities to ” Mkt Perform” on Aug 4, 2016.
Vitae Pharmaceuticals Inc. is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour its structure-based drug discovery platform. The Company has two partnered product candidates in the clinic and several wholly owned drug candidates in preclinical development. The Company’s two partnered product candidates are VTP-34072 which is in a Phase II clinical trial for the treatment of type 2 diabetes and BI 1147560 for the treatment and prevention of Alzheimer’s disease. The Company’s several wholly owned product candidates advancing in preclinical development including VTP-43742 for the treatment of autoimmune disorders VTP-38543 for the treatment of atopic dermatitis and VTP-38443 for the treatment of acute coronary syndrome.